Get started
Author

Elisabeth H. Thijssen

Observed names: Elisabeth H Thijssen, Elisabeth Thijssen, Thijssen, Elisabeth, Thijssen, Elisabeth H., Thijssen, Elisabeth Hubertina
Observed institutions: University of California, San Francisco, Amsterdam Neuroscience, University of California San Francisco Medical Center, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
ORCID: 0000-0002-9723-5441
Observed ORCID: 0000-0002-9723-5441
OpenAlex ID: A5060260970
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
2020 · Elisabeth H. Thijssen, Renaud La Joie, et al. · Nature Medicine · 758
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
2021 · Elisabeth H Thijssen, Renaud La Joie, et al. · The Lancet Neurology · 602
PDF
Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
2020 · Inge M. W. Verberk, Elisabeth Thijssen, et al. · Alzheimer s Research & Therapy · 258
PDF
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis
2020 · Steffi De Meyer, Jolien M. Schaeverbeke, et al. · Alzheimer s Research & Therapy · 100
PDF
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
2022 · Elisabeth H. Thijssen, Inge M.W. Verberk, et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 88
PDF
Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
2021 · Elisabeth H. Thijssen, Inge M. W. Verberk, et al. · Scientific Reports · 86
PDF
Relevance of biomarkers across different neurodegenerative diseases
2020 · Alexander J. Ehrenberg, Ayesha Khatun, et al. · Alzheimer s Research & Therapy · 79
PDF
Open‐Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy
2020 · Lawren VandeVrede, Marian L. Dale, et al. · Movement Disorders Clinical Practice · 57
PDF
Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
2023 · Nidhi S. Mundada, Julio C. Rojas, et al. · Alzheimer s Research & Therapy · 54
PDF
Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome
2023 · Lawren VandeVrede, Renaud La Joie, et al. · JAMA Neurology · 43
PDF
Plasma p-tau217: from ‘new kid’ to most promising candidate for Alzheimer’s disease blood test
2020 · Charlotte E Teunissen, Elisabeth H Thijssen, et al. · Brain · 26
PDF
Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease
2020 · Elisabeth H. Thijssen, Gil D. Rabinovici · JAMA Neurology · 23
Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer’s disease
2020 · Elisabeth H. Thijssen, Inge M.W. Verberk, et al. · Alzheimer s & Dementia · 19
PDF
Correction to: Relevance of biomarkers across different neurodegenerative diseases
2020 · Alexander J. Ehrenberg, Ayesha Khatun, et al. · Alzheimer s Research & Therapy · 7
PDF
An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration
2026 · Madison I. J. Honey, Yanaika S. Hok-A-Hin, et al. · Nature Medicine · 5
O3‐09‐06: a Prototype Simoa Assay Quantifying Plasma Amyloid Beta 1‐42 and 1‐40 Isoforms Can Differentiate Participants With Ad From Healthy Control Subjects
2018 · Elisabeth Thijssen, Inge M.W. Verberk, et al. · Alzheimer s & Dementia · 4
CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease
2025 · Madison I. J. Honey, Yanaika S. Hok‐A‐Hin, et al. · Alzheimer s & Dementia · 1
PDF
Comparison of two analytical platforms for blood‐based surrogate biomarkers of amyloid pathology
2020 · Steffi De Meyer, Jolien Schaeverbeke, et al. · Alzheimer s & Dementia · 1
PDF
F2‐07‐04: Plasma Amyloid Beta 1–42 and 1–40 Measured by a Novel Simoa Assay as a Diagnostic Tool for Alzheimer's Disease Pathology
2019 · Inge M.W. Verberk, Elisabeth Thijssen, et al. · Alzheimer s & Dementia · 1
PDF
Revolutionizing at‐home testing of blood‐based p ‐tau217 for early detection of Alzheimer's disease: A validation study of the Tasso Lancet Device
2025 · Elisabeth Thijssen · Alzheimer s & Dementia
PDF
Clinical performance of plasma P‐tau217 for the identification of primary Alzheimer’s disease pathology or co‐pathology in sporadic frontotemporal dementia
2024 · Igor Prufer Q C Araujo, Julio C. Rojas, et al. · Alzheimer s & Dementia
PDF
Head‐to‐head comparison between plasma ptau‐217 and Flortaucipir‐PET in amyloid‐positive patients with cognitive impairment
2022 · Nidhi S. Mundada, Elisabeth H Thijssen, et al. · Alzheimer s & Dementia
Head‐to‐head comparison between plasma ptau‐217 and Flortaucipir‐PET in amyloid‐positive patients with cognitive impairment
2022 · Nidhi S. Mundada, Elisabeth H Thijssen, et al. · Alzheimer s & Dementia
Diagnostic value of plasma P‐tau217 in frontotemporal dementia spectrum disorders
2021 · Julio C. Rojas, Lawren Vandevrede, et al. · Alzheimer s & Dementia
PDF
Comparative diagnostic performance of plasma P‐tau217 and P‐tau181 in Alzheimer’s disease and frontotemporal lobar degeneration and correlations with [18F]Flortaucipir‐PET uptake
2020 · Elisabeth H. Thijssen, Renaud La Joie, et al. · Alzheimer s & Dementia
PDF
Works count: 35
Citation count: 2,212
H-index: 13
I10-index: 13
Year
Topic
Type